ERBB2 and breast carcinoma: In women, palbociclib improves progression-free survival in ER+, HER-2– breast cancer when combined with an aromatase inhibitor (letrozole) or an ER downregulator (fulvestrant), so it received approval from the FDA and EMA (194).